Gain Therapeutics (GANX) Short-term Investments (2020 - 2024)

Gain Therapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $2.0 million for Q1 2024.

• In Q1 2024, Short-term Investments fell 82.93% year-over-year to $2.0 million; the TTM figure through Mar 2024 stood at $2.0 million (down 82.93% YoY), while the FY2023 annual figure was $5.0 million, down 61.02% from the prior year.
• Short-term Investments for Q1 2024 stood at $2.0 million, down from $5.0 million in the prior quarter.
• The five-year high for Short-term Investments was $12.8 million in Q4 2022, with the low at $10969.0 in Q2 2021.
• The 5-year median for Short-term Investments is $8.0 million (2023), against an average of $6.5 million.
• The sharpest annual moves came in 2022 and 2024: Short-term Investments soared 90514.42% in 2022, then slumped 82.93% in 2024.
• Gain Therapeutics' Short-term Investments stood at $11371.0 in 2020, then dropped by 3.54% to $10969.0 in 2021, then jumped by 116838.23% to $12.8 million in 2022, then tumbled by 61.02% to $5.0 million in 2023, then plunged by 59.61% to $2.0 million in 2024.
• Business Quant data shows GANX's Short-term Investments at $2.0 million in Q1 2024, $5.0 million in Q4 2023, and $8.0 million in Q3 2023.